Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011

Mycoses

Volumn 57, Issue 10, 2014, Pages 602-611

  Pfaller, Michael A ^a   Jones, Ronald N ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Antifungal resistance; Non albicans Candida; Surveillance

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLAVISPORA LUSITANIAE; CROSS RESISTANCE; DATA ANALYSIS; FUNGAL DETECTION; FUNGAL STRAIN; GEOGRAPHICAL VARIATION (SPECIES); HOSPITAL; NONHUMAN; SPECIES DISTRIBUTION; UNITED STATES; CLASSIFICATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HOSPITALS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 84906808738     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12206     Document Type: Article

References (46)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012; 4: 165rv13.
2. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995; 30(Suppl.): 329-38.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
4. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32.
5. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-53.
6. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis 2013; 56: 1733-4.
7. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-13.
8. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
9. Menzin J, Meyers JL, Friedman M et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711-7.
10. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
11. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-61.
12. Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis 2008; 14: 1756-8.
13. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008; 29: 978-80.
14. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012; 73: 45-48.
15. Pfaller MA, Diekema DJ. The epidemiology of invasive candidasis. In: Calderone RA, Clancy CJ (eds), Candida and Candidiasis, 2nd edn. Washington, DC: American Society for Microbiology, 2012; 449-80.
16. Pfaller MA, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-31.
17. Pfaller MA, Messer SA, Hollis RJ et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009; 47: 3185-90.
18. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67: 162-71.
19. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203.
20. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-9.
21. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
22. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52.
23. Antworth A, Collins CD, Kunapuli A et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy 2013; 33: 137-43.
24. Armstrong-James D. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 2007; 60: 459-60.
25. Riddell J, Kauffman CA. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer 2008; 112: 2334-7.
26. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
27. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011); Application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51: 2571-81.
28. Howell SA, Hazen KC. Candida, Cryptococcus, and other yeasts of medical importance. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (eds) Manual of Clinical Microbiology, 10th edn. Washington, DC: ASM Press, 2011: 1793-821.
29. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA. Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in two global surveillance programs. J Clin Microbiol 2013; 51: 117-24.
30. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 2012; 174: 259-71.
31. CLSI. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
32. CLSI. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
33. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50: 2846-56.
34. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-43.
35. Arendrup MC, Cuenca-Estrella M, Lass-Florl C. EUCAST Technical Note on the EUCASTdefinitive document EDef 7.2: method for the determination of broth dilation of broth dilution minimal inhibitory concentrations of antfungal agents for yeasts. EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E242-7.
36. Castanheira M, Woosley LN, Pfaller MA, Diekema DJ, Messer SA, Jones RN. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob Agents Chemother 2010; 54: 2655-9.
37. Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43: 2729-35.
38. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-25.
39. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.
40. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004; 25: 60-64.
41. Espinel-Ingroff A, Arendrup MC, Pfaller MA et al. Interlaboratory variability of caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the Clinical laboratory be testing this agent? Antimicrob Agents Chemother 2013; 57: 5836-42.
42. Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight species of Candida and the CLSI broth microdilution method. Antimicrob Agents Chemother 2014; 58: 916-22.
43. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. Differential in vivo activity of anidulafungin, caspofungin and micafungin against C. glabrata with and without FKS resistance mutations. Antimicrob Agents Chemother 2012; 56: 2435-42.
44. Spreghini E, Orlando F, Sanguinetti M et al. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob Agents Chemother 2012; 56: 1215-22.
45. Borman AM, Szekely A, Palmer MD, Johnson EM. Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom. J Clin Microbiol 2012; 50: 2639-44.
46. Pfaller MA, Diekema DJ, Gibbs DL et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-21.